SG11202006778TA - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- SG11202006778TA SG11202006778TA SG11202006778TA SG11202006778TA SG11202006778TA SG 11202006778T A SG11202006778T A SG 11202006778TA SG 11202006778T A SG11202006778T A SG 11202006778TA SG 11202006778T A SG11202006778T A SG 11202006778TA SG 11202006778T A SG11202006778T A SG 11202006778TA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1803439.7A GB201803439D0 (en) | 2018-03-02 | 2018-03-02 | Pharmaceutical compounds |
GBGB1814135.8A GB201814135D0 (en) | 2018-08-30 | 2018-08-30 | Pharmaceutical compounds |
PCT/IB2019/051641 WO2019167000A1 (en) | 2018-03-02 | 2019-03-01 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006778TA true SG11202006778TA (en) | 2020-08-28 |
Family
ID=65911230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006778TA SG11202006778TA (en) | 2018-03-02 | 2019-03-01 | Pharmaceutical compounds |
Country Status (18)
Country | Link |
---|---|
US (1) | US11466016B2 (en) |
EP (1) | EP3759111A1 (en) |
JP (1) | JP7326305B2 (en) |
KR (1) | KR20200127005A (en) |
CN (1) | CN111902415A (en) |
AU (1) | AU2019226480B2 (en) |
BR (1) | BR112020017283A2 (en) |
CA (1) | CA3092011A1 (en) |
IL (1) | IL276232B2 (en) |
MA (1) | MA52421A (en) |
MX (1) | MX2020008754A (en) |
NZ (1) | NZ766835A (en) |
PH (1) | PH12020551305A1 (en) |
RU (1) | RU2020130228A (en) |
SG (1) | SG11202006778TA (en) |
TW (1) | TW202000667A (en) |
WO (1) | WO2019167000A1 (en) |
ZA (1) | ZA202004729B (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (en) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
EP3601239A4 (en) | 2017-03-23 | 2020-05-13 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
SG11202006778TA (en) | 2018-03-02 | 2020-08-28 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
TW202003471A (en) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
MX2020011528A (en) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11. |
EA202190342A1 (en) * | 2018-07-24 | 2021-07-22 | Тайхо Фармасьютикал Ко., Лтд. | HETEROBICYCLIC COMPOUNDS FOR INHIBITING SHP2 ACTIVITY |
EP4356973A2 (en) | 2018-08-10 | 2024-04-24 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
CA3113233A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
TW202116773A (en) * | 2019-07-04 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | Pyrrolo[2,3-b]pyrazines as hpk1 inhibitor and the use thereof |
US20220402916A1 (en) | 2019-09-18 | 2022-12-22 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
EP4051678A1 (en) | 2019-10-28 | 2022-09-07 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
CN114901662A (en) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | Bicyclic heteroaryl compounds and uses thereof |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
EP4139299A1 (en) | 2020-04-24 | 2023-03-01 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022014640A1 (en) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Pyrimidine compound-containing combination to be used in tumor treatment |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022232320A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
CN117616031A (en) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | RAS inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
CN115340545A (en) * | 2021-05-14 | 2022-11-15 | 浙江海正药业股份有限公司 | Bicyclic heteroaryl derivative and preparation method and application thereof |
EP4347041A1 (en) | 2021-05-28 | 2024-04-10 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2522670A1 (en) | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterocyclic CRF receptor antagonists |
EP1814882A1 (en) | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
CN102311447B (en) | 2010-07-07 | 2013-11-27 | 中国科学院广州生物医药与健康研究院 | Heterocyclo pyrimidone dipeptidyl peptidase-IV (DPP-IV) inhibitor |
EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
JO3517B1 (en) | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
ES2699351T3 (en) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivatives of 1-pyridazin / triazin-3-yl-piper (-azine) / idine / pyrolidine and compositions thereof to inhibit the activity of SHP2 |
US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
ES2741746T3 (en) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compounds and compositions to inhibit SHP2 activity |
EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
CN112625028A (en) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | Compounds and compositions for inhibiting SHP2 activity |
CN107709327A (en) | 2015-06-22 | 2018-02-16 | 小野药品工业株式会社 | Brk inhibitory compounds |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
WO2017210134A1 (en) * | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
MX2018015625A (en) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2. |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (en) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
WO2018130928A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
MX2020006273A (en) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors. |
WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
SG11202006778TA (en) | 2018-03-02 | 2020-08-28 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
US20210069188A1 (en) | 2018-03-21 | 2021-03-11 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
MX2020011528A (en) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11. |
EA202190342A1 (en) | 2018-07-24 | 2021-07-22 | Тайхо Фармасьютикал Ко., Лтд. | HETEROBICYCLIC COMPOUNDS FOR INHIBITING SHP2 ACTIVITY |
IL305106A (en) | 2018-09-29 | 2023-10-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
CN112867718A (en) | 2018-09-29 | 2021-05-28 | 诺华股份有限公司 | Manufacture of Compounds and compositions for inhibiting SHP2 Activity |
GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
US20230146795A1 (en) | 2020-01-24 | 2023-05-11 | Taiho Pharmaceutical Co., Ltd. | Enhancement of anti-tumor activity of shp2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers |
-
2019
- 2019-03-01 SG SG11202006778TA patent/SG11202006778TA/en unknown
- 2019-03-01 EP EP19713584.1A patent/EP3759111A1/en active Pending
- 2019-03-01 MA MA052421A patent/MA52421A/en unknown
- 2019-03-01 KR KR1020207027598A patent/KR20200127005A/en not_active Application Discontinuation
- 2019-03-01 CN CN201980022127.4A patent/CN111902415A/en active Pending
- 2019-03-01 CA CA3092011A patent/CA3092011A1/en active Pending
- 2019-03-01 AU AU2019226480A patent/AU2019226480B2/en active Active
- 2019-03-01 BR BR112020017283-9A patent/BR112020017283A2/en unknown
- 2019-03-01 MX MX2020008754A patent/MX2020008754A/en unknown
- 2019-03-01 US US16/976,631 patent/US11466016B2/en active Active
- 2019-03-01 RU RU2020130228A patent/RU2020130228A/en unknown
- 2019-03-01 NZ NZ766835A patent/NZ766835A/en unknown
- 2019-03-01 WO PCT/IB2019/051641 patent/WO2019167000A1/en active Application Filing
- 2019-03-01 JP JP2020544607A patent/JP7326305B2/en active Active
- 2019-03-01 IL IL276232A patent/IL276232B2/en unknown
- 2019-03-04 TW TW108107099A patent/TW202000667A/en unknown
-
2020
- 2020-07-30 ZA ZA2020/04729A patent/ZA202004729B/en unknown
- 2020-08-13 PH PH12020551305A patent/PH12020551305A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2020130228A (en) | 2022-04-04 |
IL276232B1 (en) | 2023-12-01 |
JP7326305B2 (en) | 2023-08-15 |
AU2019226480B2 (en) | 2022-12-15 |
TW202000667A (en) | 2020-01-01 |
NZ766835A (en) | 2023-09-29 |
US11466016B2 (en) | 2022-10-11 |
EP3759111A1 (en) | 2021-01-06 |
WO2019167000A1 (en) | 2019-09-06 |
KR20200127005A (en) | 2020-11-09 |
AU2019226480A1 (en) | 2020-08-27 |
BR112020017283A2 (en) | 2020-12-15 |
IL276232B2 (en) | 2024-04-01 |
PH12020551305A1 (en) | 2021-10-25 |
JP2021514962A (en) | 2021-06-17 |
CA3092011A1 (en) | 2019-09-06 |
ZA202004729B (en) | 2024-02-28 |
MA52421A (en) | 2021-01-06 |
US20210107908A1 (en) | 2021-04-15 |
IL276232A (en) | 2020-09-30 |
MX2020008754A (en) | 2020-12-07 |
CN111902415A (en) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276232A (en) | Pharmaceutical compounds | |
GB2569961B (en) | Pharmaceutical | |
GB2572126B (en) | Pharmaceutical | |
GB201911928D0 (en) | Pharmaceutical compounds | |
GB2572125B (en) | Pharmaceutical | |
GB201810245D0 (en) | Pharmaceutical compounds | |
GB201709652D0 (en) | Pharmaceutical compounds | |
GB201704965D0 (en) | Pharmaceutical compounds | |
GB201704714D0 (en) | Pharmaceutical compounds | |
GB201703881D0 (en) | Pharmaceutical compounds | |
GB201810239D0 (en) | Pharmaceutical compounds | |
GB201911944D0 (en) | Pharmaceutical compounds | |
GB201819961D0 (en) | Pharmaceutical compounds | |
GB201706806D0 (en) | Pharmaceutical compounds | |
IL277334A (en) | Pharmaceutical combinations | |
IL291570A (en) | Pharmaceutical compounds | |
GB201914910D0 (en) | Pharmaceutical compounds | |
GB201704966D0 (en) | Pharmaceutical compounds | |
GB201819960D0 (en) | Pharmaceutical compounds | |
GB201801562D0 (en) | Pharmaceutical compounds | |
GB201800378D0 (en) | Pharmaceutical compounds | |
IL279334A (en) | Pharmaceutical combinations | |
GB201816369D0 (en) | Pharmaceutical compounds | |
GB201915932D0 (en) | Pharmaceutical compounds | |
GB201915273D0 (en) | Pharmaceutical compounds |